IR Biosciences Holdings, Inc. Share Price

Equities

IRBS

US46264M3034

Biotechnology & Medical Research

Market Closed - OTC Markets 01:10:00 12/12/2023 GMT 5-day change 1st Jan Change
0.000001 USD -.--% Intraday chart for IR Biosciences Holdings, Inc. -.--% -.--%
Sales 2009 - Sales 2010 - Capitalization 1.2M 95.44M
Net income 2009 -6M -479M Net income 2010 -5M -399M EV / Sales 2009 -
Net Debt 2009 5.81M 464M Net Debt 2010 3.67M 293M EV / Sales 2010 -
P/E ratio 2009
-0.37 x
P/E ratio 2010
-0.2 x
Employees 4
Yield 2009 *
-
Yield 2010
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
3 years
0.00
Extreme 0
0.00
5 years
0.00
Extreme 0
0.09
10 years
0.00
Extreme 0
0.09
More quotes
Managers TitleAgeSince
Chief Executive Officer - 30/06/03
Director of Finance/CFO 70 30/11/04
Members of the board TitleAgeSince
Chief Executive Officer - 30/06/03
More insiders
IR BioSciences Holdings, Inc. is a development-stage biotechnology company. The Company, through its wholly owned subsidiary, ImmuneRegen BioSciences, Inc. (ImmuneRegen), is engaged in the research and development of the drug candidate Homspera for use in therapies in pulmonology, immunology and hematology. The Company focuses on the research and development of therapies in the areas of pulmonary fibrosis, influenza infection and radiation-induced Neutropenia. Other areas of research include vaccine adjuvant activity evinced against certain forms of cancer and applications for wound healing and for regenerating or strengthening the human immune system, in part, through stimulating human adult stem cells.
More about the company